Research programme: cancer and sepsis therapeutics - TaiRx

Drug Profile

Research programme: cancer and sepsis therapeutics - TaiRx

Alternative Names: EFP 306; Rexis; TRX 306; TRX 606

Latest Information Update: 31 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TaiRx
  • Class Anti-infectives; Antineoplastics
  • Mechanism of Action Growth inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Sepsis

Most Recent Events

  • 29 Jul 2015 Preclinical trials in Cancer in Taiwan before July 2015 (PO)
  • 29 Jul 2015 Preclinical trials in Sepsis (Adjunctive treatment) in Taiwan before July 2015 (unspecified route)
  • 29 Jul 2015 TaiRx files IND application for TRX 306 for Sepsis in Taiwan, before June 2015 (TaiRx website, June 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top